1. Background
2. Methods
2.1. Patients
2.2. Ethical Considerations
2.3. Inclusion and Exclusion Criteria
2.4. Randomization
2.5. Blinding Method
2.6. Groups and Interventions
2.7. Outcomes
2.8. Sample Size
2.9. Statistical Analysis
3. Results
| Variables | Etomidate Group (n = 39) | Thiopental-Midazolam Group (n = 39) | P-Value |
|---|---|---|---|
| Age, y | 45 ± 17.9 | 45.9 ± 15.8 | 0.82 |
| Weight, kg | 66.2 ± 6.3 | 67.3 ± 6.2 | 0.42 |
| Height, cm | 16.8 ± 6.4 | 169.9 ± 5.9 | 0.201 |
| BMI, kg/m2 | 23.4 ± 1.53 | 23.30 ± 1.49 | 0.78 |
| Gender | 0.65 | ||
| Male | 22 (56.4) | 26 (61.5) | |
| Female | 17 (43.6) | 15 (38.5) | |
| ASA | 0.36 | ||
| 1 | 16 (41) | 20 (51.3) | |
| 2 | 23 (59) | 19 (48.7) |
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists.
a Values are presented as No. (%) or mean ± SD.
| Variables | Time | Etomidate Group (n = 39) | Thiopental-Midazolam Group (n = 39) | P-Value a |
|---|---|---|---|---|
| Heart rate (bit per minute) | T1 | 81.2 ± 17.3 | 84.4 ± 16.5 | 0.40 |
| T2 | 81.3 ± 17.2 | 87.5 ± 16.7 | 0.066 | |
| T3 | 82.2 ± 17.2 | 86.1 ± 12.1 | 0.24 | |
| T4 | 89.7 ± 16.7 | 91.2 ± 18 | 0.71 | |
| T5 | 82.7 ± 15.3 | 85.2 ± 13.7 | 0.45 | |
| T6 | 76.9 ± 14.5 | 81.3 ± 12.3 | 0.16 | |
| T7 | 74.3 ± 14.4 | 80.4 ± 13.8 | 0.59 | |
| P b | < 0.001 | < 0.001 | 18 c | |
| SBP (mmHg) | T1 | 135.1 ± 17 | 131 ± 16.3 | 0.28 |
| T2 | 123.5 ± 21.4 | 120.3 ± 21.3 | 0.52 | |
| T3 | 120.9 ± 23.4 | 118.7 ± 19.4 | 0.66 | |
| T4 | 146.5 ± 26.9 | 135.5 ± 23.8 | 0.062 | |
| T5 | 128.8 ± 21.8 | 132.2 ± 20.3 | 0.24 | |
| T6 | 125.6 ± 25.3 | 116.8 ± 18.5 | 0.08 | |
| T7 | 119.9.6 ± 20.8 | 113.8 ± 17 | 0.18 | |
| P b | < 0.001 | < 0.001 | 0.12 c | |
| DBP (mmHg) | T1 | 86.7 ± 11.8 | 82.4 ± 11.9 | 0.20 |
| T2 | 76.1 ± 15.9 | 75.7 ± 16.9 | 0.93 | |
| T3 | 87.7 ± 19.3 | 75.5 ± 17.9 | 0.48 | |
| T4 | 91.9 ± 19.3 | 84.7 ± 18.5 | 0.096 | |
| T5 | 79.3 ± 12.4 | 76.6 ± 17 | 0.42 | |
| T6 | 77 ± 17.3 | 71.2 ± 15.4 | 0.12 | |
| T7 | 78 ± 19.2 | 69 ± 16.4 | 0.029 | |
| P b | < 0.001 | < 0.001 | 0.07 c | |
| MAP (mmHg) | T1 | 10.4.3 ± 14.8 | 100.2 ± 13.7 | 0.21 |
| T2 | 10.4.3 ± 19 | 921. ± 18.6 | 0.86 | |
| T3 | 93.6 ± 22 | 92.1 ± 18.8 | 0.75 | |
| T4 | 112.3 ± 20.2 | 105.7 ± 21.8 | 0.17 | |
| T5 | 97.1 ± 15.5 | 94.6 ± 18.4 | 0.52 | |
| T6 | 95.7 ± 21.9 | 87.6 ± 17.3 | 0.074 | |
| T7 | 93.8 ± 19.5 | 84.5 ± 15.8 | 0.023 | |
| P b | < 0.001 | 0.006 | 0.20 c | |
| SpO2 (%) | T1 | 96.5 ± 2.6 | 96.7 ± 2.8 | 0.15 |
| T2 | 97.7 ± 1.9 | 97.5 ± 6.5 | 0.79 | |
| T3 | 98.4 ± 1.4 | 97.9 ± 6 | 0.66 | |
| T4 | 97.9 ± 2.2 | 98.3 ± 3.3 | 0.60 | |
| T5 | 98.5 ± 1.2 | 98.2 ± 4.6 | 0.74 | |
| T6 | 98.5 ± 1.2 | 98 ± 5 | 0.5 | |
| T7 | 98.4 ± 1.4 | 97.9 ± 4.9 | 0.5 | |
| P b | < 0.001 | 0.24 | 0.92 c |
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; SpO2, peripheral blood oxygen saturation.
a Significant level of difference between two groups at each point of time according to the t-test.
b Significant level of parameter changes within each group according to variance analysis test with repeated observations.
c Significant level of the process of parameter changes between two groups according to the analysis of variance test with repeated observations.
| Variables | Etomidate Group (n = 39) | Thiopental-Midazolam Group (n = 39) | P-Value |
|---|---|---|---|
| Laryngoscopy grade | 0.83 | ||
| 1 | 21 (53.8) | 22 (56.4) | |
| 2 | 15 (38.5) | 12 (30.8) | |
| 3 | 2 (5.1) | 3 (7.7) | |
| 4 | 1 (2.6) | 2 (5.1) | |
| Mean laryngoscopy time (sec) | 10.79 ± 2.66 | 12.13 ± 2.22 | 0.019 |
| Adverse response to laryngoscopy | 0. 19 | ||
| Hypertension | 5 (12.8) | 1 (2.6) | |
| Tachycardia | 1 (2.6) | 0 (0) | |
| Cough | 0 (0) | 2 (5.1) | |
| Movement | 3 (7.7) | 2 (5.1) | |
a Values are presented as No. (%).
